Future of Immunotherapy Could be ‘Off-the-Shelf` Treatments
(World News Science)

In a new commentary for the journal Science, an associate vice president for research at The University of Texas at Arlington argues that emerging protein-based immunotherapies could lead to highly effective “off-the-shelf” cancer treatments for more patients. Jon Weidanz, who also is a professor in the College of Nursing and Health Innovation at UTA, is the author of a perspective regarding the development of cancer immunotherapies. His article, “Targeting cancer with bispecific antibodies,” will appear in the March 5 edition of Science. It evaluates the findings of three studies by researchers at Johns Hopkins University and proposes that an emerging method of protein-based immunotherapy...